Shandong Buchang Pharmaceuticals Co Ltd

Buchang Pharmaceutical announced on September 29 that its wholly owned subsidiary Tonghua Guhong signed a technology transfer contract with Jilin Province Tiantai Pharmaceutical Co., Ltd. to acquire the production approval and technology ownership of Angong Niuhuang Wan for a transfer price of 9.4 million yuan. In the first half of 2026, Buchang Pharmaceutical achieved revenue of 5.003 billion yuan and net profit attributable to the parent of 503 million yuan.

Buchang Pharmaceuticals announced that its controlling subsidiary Buchang Yingxi Trading has completed the industrial and commercial registration change for its capital increase and obtained a renewed business license, with registered capital increased from 1 million yuan to 5 million yuan. The company approved the capital increase proposal at the 52nd meeting of the fifth board of directors on July 21, 2026, making a cash capital increase at 1 yuan per share in proportion to its shareholding, and will continue to hold 90 percent equity in Buchang Yingxi Trading after completion. Buchang Yingxi Trading was established on February 14, 2025, with Zhang Chuang as its legal representative. Its business scope covers wholesale of daily necessities, wholesale of medical masks, sales of health food, sales of disinfectants, and sales of Class I and Class II medical devices.

Buchang Pharma's controlling subsidiary Sichuan Luzhou Buchang Biopharmaceutical has had its clinical trial application for a new indication of BC008-1A injection accepted by the National Medical Products Administration. BC008-1A is a bispecific antibody specifically targeting PD-1 and TIGIT. The proposed new indication is for use in combination with bevacizumab for the treatment of recurrent CNS WHO grade 4 glioma in adults. As of July 31, 2026, cumulative R&D investment in this product was approximately 115 million yuan, and no bispecific antibody drug targeting the same targets has been approved for marketing domestically or internationally.

Buchang Pharma announced that its wholly owned subsidiaries Buchang Gaoxin and Shaanxi Buchang Pharma completed changes to their Drug Manufacturing Licenses on July 24, 2026. Buchang Gaoxin added a contract manufacturing scope for capsules, added a pre-extraction workshop, a hard capsule production line in Solid Workshop II, and a tablet production line in Solid Workshop I, with its classification code changed to AhzChz. Shaanxi Buchang Pharma added production lines for Pramipexole Dihydrochloride Extended-Release Tablets and Suanzaoren Dihuang Capsules, removed the contract manufacturing scope for Kechuan'an Oral Liquid, and changed its classification code to AhzBhzCh.

Baoding Tianhao, a wholly owned subsidiary of Buchang Pharma, has signed two technology development entrustment contracts with Beijing Xinliyan, commissioning the latter to carry out the research and development, registration application, and entrusted manufacturing of injectable silk fibroin filler and injectable hydroxyapatite filler. Both products are national Class III medical devices, intended respectively for the treatment of midface volume loss and mandibular contour deficiency. All ownership, intellectual property rights, and revenue rights of the collaborative products belong exclusively to Baoding Tianhao. The transaction amount is exempt from disclosure due to commercial confidentiality.

Buchang Pharma announced that two exclusive products, Kangfuyan Capsules and Mudan Granules, have been newly included in the 2026 edition of the National Essential Medicines List, which will take effect from September 1, 2026. The sales revenue of these two products in 2025 was 136 million yuan and 195 million yuan respectively. The company and its controlled subsidiaries have a total of 104 products included in the Essential Medicines List. In the first quarter of 2026, Buchang Pharma achieved revenue of 2.579 billion yuan and net profit attributable to the parent company of 320 million yuan.